UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with margin leverage, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche announces FDA approves Evrysdi tablet to treat SMA
- Roche initiated with an Equal Weight at Morgan Stanley
- Balanced Outlook on Roche Holding Amid Gazyva’s Promising Yet Uncertain Prospects
- Recursion Pharmaceuticals’ (RXRX) AI Approach to Drug Discovery Shows Progress
- Trump Trade: President advocates to close carried interest tax loophole